| Description | This product is a human monoclonal antibody that reacts with APP. The antibody is expressed with mammalian cell transient expression system, serum-free and purified by affinity chromatography. The purity and integrity are tested via SDS-PAGE and SEC-HPLC analysis. Given an antigen, additional QC measures are also desired such as affinity testing and binding validation. Specifically, the antibody is provided in multiple formats for in vivo and in vitro assays. The Invivo version features greater than 95% purity, ultra-low endotoxin levels (<1 EU/mg or 0.1 EU/mg), and is preservative, stabilizer, and carrier protein-free. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | Human |
| Isotype | IgG |
| Expression Species | HEK293F or CHO |
| Conjugation | None |
| Purity | >95%, determined by SDS-PAGE and/or SEC-HPLC |
| Endotoxin | <1 EU/mg, determined by LAL method |
| Purification | Protein A affinity purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4⁰C within a week. For longer storage, aliquot and store at -20⁰C. |
| Application | WB; FuncS; IF; Neut; ELISA; FC; IP; ICC |
| Application Notes | The antibody is recommended for detection of APP by FuncS, IF, Neut, ELISA, FC, IP, ICC assays. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
Figure 1 Anti-APP Monoclonal Antibody (V3S-0622-YC4117) in SDS-PAGE
SDS-PAGE analysis of V3S-0622-YC4117 in non-reduced (lane 1, 2.5 μg) and reduced (lane 2, 2.5 μg) conditions. Gel stained for 30 minutes with Coomassie Blue. As a result of different β-mercaptoethanol-reduced proteins (Heavy chain and Light chain) migrate as about 50 kDa and 25 kDa, respectively.
Figure 1 Anti-APP Monoclonal Antibody (V3S-0622-YC4117) in SDS-PAGE
Figure 2 Anti-APP Monoclonal Antibody (V3S-0622-YC4117) in SEC-HPLC
The purity of V3S-0622-YC4117 was greater than 95% as determined by SEC-HPLC.
Column: 3 µm, 7.8 x 300 nm
Mobile phase: 150 mM Sodium Phosphate Buffer, pH 7.0
Detection: UV 280 nm
Injection: 10 µl
Figure 2 Anti-APP Monoclonal Antibody (V3S-0622-YC4117) in SEC-HPLC
Figure 3 Anti-APP Monoclonal Antibody (V3S-0622-YC4117) in WB
Western blot analysis was performed by loading 1 µg (lane 1, Non-Reduced) and 1 µg (lane 2, Reduced) recombinant human Beta-amyloid 42 with His & GST Tag (10703-H20E2) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least 1 hour. Membranes were probed with Anti-Human Abeta Antibody (V3S-0622-YC4117) at a concentration of 1 μg/mL overnight at 4°C on a rocking platform. Then probed with Goat anti-Human IgG HRP secondary antibody at a dilution of 1:8,000 for one hour. Chemiluminescent was detected.
Figure 3 Anti-APP Monoclonal Antibody (V3S-0622-YC4117) in WB
Figure 4 Anti-APP Monoclonal Antibody (V3S-0622-YC4117) in ELISA
ELISA analysis of V3S-0622-YC4117 was performed by coating with recombinant human Beta-amyloid 42 with His & GST Tag (10703-H20E2) (1 μg/mL). Then blocked with BSA and incubated with Anti-Human APP Antibody (V3S-0622-YC4117) at a starting concentration of 2.5 ng/mL. The HRP-conjugated goat anti-human IgG as a secondary antibody. Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.
Figure 4 Anti-APP Monoclonal Antibody (V3S-0622-YC4117) in ELISA
